Sandoz Confirms European Commission Approval of Pyzchiva^® (Ustekinumab), Further Strengthening Immunology Offering

Sandoz announces that the European Commission has granted marketing authorization for Pyzchiva® (biosimilar ustekinumab), developed and registered by Samsung Bioepis.